- Home
- ESPR vs REFI Comparison
ESPR vs REFI Comparison
Compare ESPR & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- REFI
- Stock Information
- Founded
- ESPR 2008
- REFI 2021
- Country
- ESPR United States
- REFI United States
- Employees
- ESPR N/A
- REFI N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- REFI Real Estate Investment Trusts
- Sector
- ESPR Health Care
- REFI Real Estate
- Exchange
- ESPR Nasdaq
- REFI Nasdaq
- Market Cap
- ESPR 305.0M
- REFI 314.2M
- IPO Year
- ESPR 2013
- REFI 2021
- Fundamental
- Price
- ESPR $1.63
- REFI $15.42
- Analyst Decision
- ESPR Buy
- REFI Strong Buy
- Analyst Count
- ESPR 7
- REFI 3
- Target Price
- ESPR $6.36
- REFI $20.00
- AVG Volume (30 Days)
- ESPR 4.5M
- REFI 138.4K
- Earning Date
- ESPR 03-04-2025
- REFI 03-12-2025
- Dividend Yield
- ESPR N/A
- REFI 13.38%
- EPS Growth
- ESPR N/A
- REFI N/A
- EPS
- ESPR N/A
- REFI 1.88
- Revenue
- ESPR $332,314,000.00
- REFI $55,534,183.00
- Revenue This Year
- ESPR $5.51
- REFI $20.42
- Revenue Next Year
- ESPR $1.42
- REFI N/A
- P/E Ratio
- ESPR N/A
- REFI $8.19
- Revenue Growth
- ESPR 185.66
- REFI N/A
- 52 Week Low
- ESPR $1.47
- REFI $14.82
- 52 Week High
- ESPR $3.94
- REFI $16.47
- Technical
- Relative Strength Index (RSI)
- ESPR 45.89
- REFI 40.85
- Support Level
- ESPR $1.47
- REFI $15.32
- Resistance Level
- ESPR $1.75
- REFI $15.67
- Average True Range (ATR)
- ESPR 0.11
- REFI 0.29
- MACD
- ESPR 0.03
- REFI -0.05
- Stochastic Oscillator
- ESPR 57.14
- REFI 29.57
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.